Montreal, Quebec--(Newsfile Corp. - April 4, 2024) - Thryv Therapeutics Inc., a Montreal based biotechnology company pioneering a precision medicine approach to treat indications including Congenital Long QT Syndrome (LQTS), atrial fibrillation, and heart failure, will be participating in the 2024 Bloom Burton & Co. Healthcare Investor...